Bellevue Group Ag C4 Therapeutics, Inc. Transaction History

Bellevue Group Ag

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$5.3 - $11.0 $23,320 - $48,400	-4,400 Reduced 7.1%	57,600 $470,000
Q4 2023 Feb 14, 2024	BUY	$1.18 - $6.03 $73,160 - $373,860	62,000 New	62,000 $350,000
Q2 2022 Aug 11, 2022	SELL	$5.06 - $26.46 $275,770 - $1.44 Million	-54,500 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$19.99 - $33.23 $145,927 - $242,578	7,300 Added 15.47%	54,500 $1.32 Million
Q3 2021 Nov 12, 2021	BUY	$35.91 - $50.5 $581,742 - $818,100	16,200 Added 52.26%	47,200 $2.11 Million
Q2 2021 Aug 12, 2021	BUY	$30.39 - $42.18 $942,090 - $1.31 Million	31,000 New	31,000 $1.17 Million

130

63.5M

670K

54.8K

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $208M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

Stay updated on Bellevue Group Ag with notifications on news.